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Abstract: Mice were immunized 3 times intranasally (i.n.) at intervals of 2 weeks with a formalin-inactivated Sendai virus (SV) whole
virus with and without whole formalin-inactivated Bordetella pertussis (Bp) as adjuvant. The antibody response to SV was measured
using the hemagglutination inhibition (HI) test in serum, and the IgA and IgG antibodies were evaluated using enzyme linked
immunosorbent assay in saliva and serum. It was demonstrated that repeating immunizations with SV plus Bp could induce HI serum
antibodies, IgA and serum IgG antibodies. However, in mice immunized subcutaneously with SV alone, high serum IgG antibodies
and HI titers were induced only. In contrast, the animals immunized i.n. with SV alone had significantly lower titers to SV than those
of the other groups.
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Introduction
Sendai virus (SV) is a murine parainfluenza virus type
1 (MPIV1) (parainfluenza family), which is formed in
mice, rats, hamsters and guinea pigs. It causes a typical
respiratory infection and has often been used as a model
for respiratory virus infections (1-5). It has also been
demonstrated serologically that this infection occurs fairly
often in pigs (6). The natural hosts of SV have not been
clearly identified, but the virus is referred to here as
MPIV1 because it infects mice efficiently, causes disease,
and spreads readily to uninfected animals (4).
Although SV is often referred to as MPIV1, this
species designation is based on its permissiveness during
laboratory infection rather than evidence from nature.
Indeed, there is a lack of virologic or serologic evidence of
MPIV1 in wild mouse populations (2), and the natural
host (or hosts) of MPIV1 remains unknown.
Several studies on animals have shown that vaccines
consisting of inactivated parainfluenza virus, or
components of the virus, may also be immunogenic when
given intranasally (i.n.) (7-9).
Non-replicating mucosal vaccines containing killed
microbes, or parts thereof, may represent an alternative

to vaccines maintaining live attenuated microorganisms
that themselves carry some risk of causing disease.
Results from animal studies, however, suggest that this
kind of vaccine based on components of microbial origin
may be effective only if so-called mucosal adjuvants are
added (10).
It has recently been shown that whole meningococci,
as well as formalin-inactivated Bordetella pertussis (Bp),
are able to enhance both systemic and mucosal antibody
responses to the nasal viral vaccine that is weakly
immunogenic in itself (11).
The secretion of vaccine-specific IgA-antibodies onto
the mucosal surfaces, being the result of local mucosal
stimulation, has been proposed as the most important
advantage of mucosal vaccines (12,13). Non-replicating
nasal vaccines may be thus developed as an alternative to
corresponding vaccines for injection such as parainfluenza
1 virus (14).
The aim of the present study was the assessment of
the efficacy of intranasal immunization of mice with
formalin-inactivated whole SV, with and without Bp as
mucosal adjuvant, and the results were compared with
separate groups of mice immunized subcutaneously (s.c.)
without adjuvant. The efficiency of the systemic and
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mucosal immunospecific response was evaluated by
measurement of antibodies to SV, i.e. IgG and HI in
serum as well as IgA in saliva.

Group 3, SV and PBS. An immunogen mixture
containing 5 µg of SV in PBS was administered s.c.

Materials and Methods

All groups were immunized 3 times at intervals of 2
weeks. During the intranasal immunizations (Groups 1,2
and 4) the upper part of the nose was held down to
minimize the possibility of the mixture being swallowed
or entering the trachea directly. The immunogen mixture
(30 µl) was delivered slowly with a micropipette into the
nares so that the mouse could sniff it in. For
subcutaneous immunization, 0.2 ml of PBS containing the
SV was s.c. injected into a dorsal site on the mice. Animals
were not anesthetized during immunization.

Groups of BALB/c mice, 6 inbred females in each, 7 to
8 weeks old and weighing 18 ± 2.0 g, were obtained
from the breeding unit of the Institute of Immunology,
Vilnius University (Lithuania). The animals were kept in a
corridor system under conditions of a semibarrier type in
type T-3 cages (Velaz, Prague, Czech Republic), 6 animals
per cage.
Chips of deciduous trees, sterilized at 120 °C for 20
min, were used for bedding. The bedding was changed
twice weekly. Temperature was maintained at 20 ± 2 °C.
Illumination was provided by daylight lamps for 12 h per
day. Ventilation was provided by the circulation of
unfiltered air (0.5 m3/s). Relative humidity and noise
were maintained at 55 ± 5% and 50 dB, respectively.
Food granules were produced by a manufacturer in
Alytus (Lithuania). The chow contained gross energy at
13.6 MJ/kg, crude protein (20%), crude oil (6.2%), and
crude fiber (3.9%). The feed was balanced in terms of
amino acids and vitamins. Water was provided ad libitum.
SV strain Fushimi was obtained from the Institute of
Virology (Moscow, Russia) and was grown, purified by
ultracentrifugation at 20,000 x g for 2 h at 4 °C and
inactivated as described previously (15).
Pertussis vaccine used as a source of Bp was obtained
from the State Institute of Sera, Copenhagen, Denmark.
Commercial vaccine contained formalin - inactivated
whole Bp. Prior to use the Bp was concentrated by
centrifugation at 7000 x g at 10 °C for 20 min. The
formalin-inactivated whole SV and Bp, as bacterial
adjuvant, were mixed immediately before immunization.
The study consisted of 4 treatment groups with 6
mice in each group. The treatment groups were as
follows:
Group 1, SV and phosphate buffered saline pH 7.2
(PBS). An immunogen mixture containing 28 µg of SV in
PBS was used for immunization.
Group 2, SV and Bp. An immunogen mixture
containing 28 µg of SV and 20 µg of Bp in PBS was used
for immunization.
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Group 4, Placebo (PBS). PBS was used for
immunization.

Samples of saliva and serum were collected as
described previously (16) on days 28 and 42 after the
first immunization.
SV-specific IgA antibodies in saliva and SV-specific IgG
antibodies in serum were analyzed using enzyme linked
immunosorbent assay (ELISA) as described previously
(16). The antibody titers were expressed as the reciprocal
of the highest dilution of serum or saliva in which optical
density (492 nm) was 2-fold higher than that of the
negative samples. The titers were converted to a base-2
logarithmic scale.
Anti-SV virus antibody titers in serum samples were
measured using HI as described previously (15). The
antibody titers were expressed as the reciprocal of the
highest dilution of serum at which complete inhibition of
hemagglutination was seen and the titers were converted
to a base-2 logarithmic scale.
The protein content of inactivated SV and Bp was
measured as described earlier (17).
We performed the experiment on mice after having
received permission No. 0086 from the Ethics Committee
on the Use of Laboratory Animals of the State Food and
Veterinary Service.
The means of the IgA, IgG, and HI antibody titers
were compared using 2-tailed Student’s t-test. All values
were expressed as mean ± standard deviation and were
considered statistically significant at P < 0.05.
Results
The efficacy of experimental formulations was
evaluated by measuring IgA, IgG and HI antibody titers in
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20

SV alone, i.n.

*

12
*

SV alone, s.c.
IgA titer, log 2

*

*

4
*

*

l
28
42
Days after the first immunization

SV + Bp, i.n.

*

Placebo, i.n.

*

6

Placebo, i.n.

8

SV alone, i.n.

8

SV alone, s.c.

*

0
10

SV + Bp, i.n.

*

16
IgG titer, log 2

mice on days 28 and 42 after the first immunization.
After intranasal immunization immunospecific anti-SV IgA
antibodies were recorded (Figure 1). However, there was
no difference in responses between the SV plus Bp and SV
alone groups. The responses after intranasal
immunization with SV alone were significantly lower than
responses obtained with intranasal immunization with SV
plus Bp on day 42 after the first immunization. Notably,
the IgA titers were significantly increased on days 28 and
42 after the first immunization in each of the
experimental groups of mice.

Figure 2. Serum IgG antibody responses in mice after intranasal and
subcutaneous immunizations with SV alone or admixed with
Bp.
Asterisks indicate groups the values of which significantly
differ from those of others on the same day.
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Figure 1. Saliva IgA antibody responses in mice after intranasal and
subcutaneous immunizations with SV alone or admixed with
Bp.
Asterisks indicate groups the values of which significantly
differ from those of others on the same day.
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In contrast, all animals immunized s.c. with SV alone
had significantly higher HI titers to SV than did those
injected i.n. with either SV alone or SV plus Bp on day 28
after the first immunization. Furthermore, HI titers
induced after 2 or 3 intranasal immunizations with SV
alone were significantly lower than those of the other
experimental groups of mice (Figure 3). The animals that
received SV plus Bp demonstrated significantly higher HI
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The IgG titers induced with subcutaneous
immunization with SV alone were significantly higher
than those obtained with intranasal immunization with
either SV alone or SV plus Bp on days 28 and 42 after the
first immunization (Figure 2), while the IgG titers to SV
after immunization with SV plus Bp were 1.24 and 1.34fold higher, respectively, than those of mice injected i.n.
with SV alone on days 28 and 42 after the first
immunization.
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Figure 3. Serum HI antibody responses in mice after intranasal and
subcutaneous immunizations with SV alone or admixed with
Bp.
Asterisks indicate groups the values of which significantly
differ from those of others on the same day.

titers to SV than mice immunized either i.n. or s.c. with
SV alone on day 48 after the first immunization (Figure
3). After the third immunization in all experimental
groups of mice, HI titers were significantly increased,
11.5, 1.85, and 1.2-fold, respectively.

Discussion
We demonstrated that repeated intranasal
immunizations with SV plus Bp could also prime the
immune system for both mucosal and systemic antibody
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responses. Thus, the high titers to SV in saliva in Groups
1 and 2, indicate that induction of antibody responses
took place in the upper airway mucosa. Furthermore, the
animals immunized either i.n. or s.c. with SV alone
showed high serum IgG antibodies and HI antibody titers.
Induction of both systemic and mucosal antibody
responses is a desirable characteristic of i.n. delivered
vaccines (18).
The assumption that Bp may influence immune
responses to antigens delivered on the mucosa by
interfering with immunological processes below the
mucosal surfaces is supported by the observation that
preparations of whole-cell pertussis vaccines have a
potent adjuvant effect when injected with other vaccine
antigens (19).
These findings suggest that repeated immunizations
with whole virus admixed with bacteria-derived

components as mucosal adjuvants may thus allow for
immunological memory to develop as well as formation of
the protection mechanism against viral infection in mice
(20).
Dissemination of the mucosal and systemic responses
among mice receiving the SV plus Bp vaccine i.n. was
marked. The discrepancy among the responses of these
groups of mice may be due to the difference in physical
form and composition of adjuvants, i.e. whole virus and
Bp have different bioadhesive sites for absorption on the
epithelial airway cells (21). Therefore, a modulation of
these immunocompetent cells induced diverse levels of
immunospecific responses.
Our results suggest that Bp, which is bacteriumderived and was used as an adjuvant for animal nasal
vaccine, is a suitable candidate adjuvant for further
studies.
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